 |
|
|
| |
DDIs (drug-drug interactions) in the evolving HCV treatment landscape
|
| |
| |
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington DC; May 19-21, 2014
Saye Khoo
Institute of Translational Medicine
University of Liverpool
15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy
May 19- 21, 2014, Washington, DC
Single-Dose Pharmacokinetics of Daclatasvir (DCV; BMS-790052) in Subjects With Hepatic Impairment Compared With Healthy
Subjects......http://www.natap.org/2011/AASLD/AASLD_78.htm.....Bifano AASLD 2011
Daclatasvir (DCV; BMS-790052) Has No Clinically Significant Effect on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects.......http://www.natap.org/2011/AASLD/AASLD_77.htm Bifano AASLD 2011
CROI/2012: Assessment of HIV Antiretroviral Drug Interactions With the HCV NS5A Replication Complex Inhibitor Daclatasvir Demonstrates a PK Profile Which Supports Coadministration With Tenofovir, Efavirenz and Atazanavir/r http://www.natap.org/2012/CROI/croi_38.htm
15th Intl Wrkshp Clinical Pharm HIV Therapy ABT-450/Ritonavir +Ombitasvir + Dasabuvir: Drug Interactions Mediated by Transporters - (05/21/14)
The Effect of Hepatic Impairment on the Safety, Pharmacokinetics, and Antiviral Activity of GS-7977 in Hepatitis C Infected Subjects Treated for Seven Days.....http://www.natap.org/2012/EASL/EASL_47.htm Lawitz EASL 2012
15th Intl Wrkshp Clinical Pharm HIV Therapy Drug Interactions Between Direct-Acting anti-HCV Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals - (05/22/14)
15th Intl Wrkshp Clinical Pharm HIV Therapy Gilead - Transporters: Role in Clinical Development of HCV Compounds - (05/23/14)
AASLD: Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects With Moderate or Severe Hepatic Impairment - (11/11/13)
AASLD: Lack of a Clinically Important Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and Sofosbuvir (SOF) or Ledipasvir (LDV) in HCV-Uninfected Female Subjects - (11/11/13)
|
| |
|
|
|
|
|
